Current partner codePEPTIDESDE
NCT06784752·Phase 3·INTERVENTIONAL

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Status

Recruiting

Phase

Phase 3

Enrollment

240

Locations

65

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden

Full detailed description

The study consists of a screening phase, a treatment phase and a follow-up phase. This study compares treatment with \[177Lu\]Lu-DOTA-TATE plus octreotide LAR and octreotide LAR only.

Interventions

Treatment arms and agents.

RADIATION

[177Lu]Lu-DOTA-TATE

\[177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)

DRUG

Octreotide LAR

Octreotide LAR will be administered Q8W when co-administered with \[177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W. In the control arm Octreotide LAR will be administered Q4W.

Timeline

From registration to results.

  1. First posted

    Jan 20, 2025

  2. Study start

    May 30, 2025

  3. Primary completion

    Dec 8, 2028

  4. Study completion

    Jan 23, 2034

  5. Results posted

    Not reported

  6. Registry updated

    Apr 30, 2026

Outcomes

What the study measures.

Primary outcomes

Progression Free Survival (PFS) centrally assessed by Blinded Independent Review Committee (BIRC)

Time frame · After observing approximately 88 PFS events as per BIRC assessments, expected after approximately 33 months from study start

PFS is defined as the time from randomization to the first occurrence of progression (centrally assessed by Blinded Independent Review Committee (BIRC) according to RECIST v1.1) or death due to any cause.

Secondary outcomes

Time to Deterioration (TDD) (Key Secondary)

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

Time to deterioration is defined as the time from randomization to the first occurrence of a deterioration compared to the baseline scores or death from any cause for each of the following domains (tested separately) of EORTC QLQ-GI.NET21 \[gastrointestinal scale (GI scale)\] and EORTC QLQ-C30 questionnaires (fatigue, diarrhea, and global health scale).

Progression Free Survival (PFS)

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

PFS is defined as the time from randomization to the first occurrence of progression (Investigator assessed according to RECIST v1.1) or death due to any cause.

Objective Response Rate (ORR)

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

ORR: Rate of participants with best overall response (BOR) of partial response (PR) or complete response (CR) as per RECIST v1.1 (both Investigator and centrally assessed by BIRC).

Disease Control Rate (DCR)

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

DCR: Rate of participants with BOR of PR, CR or stable disease (SD) as per RECIST v1.1 (both Investigator and centrally assessed by BIRC).

Duration of Response (DOR)

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

DOR: The time from initially meeting the criteria for response (CR or PR) until the time of progression according to RECIST v1.1 or death due to underlying disease only.

Overall Survival (OS)

Time frame · Until 60 month from randomization

OS: Time from the randomization date until the date of death due to any cause.

Time to Deterioration (TDD)

Time frame · At the time of primary PFS analysis after observing approximately 88 PFS events per BIRC assessment

TTD is the time from randomization to the first occurrence of a deterioration compared to the baseline scores or death from any cause for EORTC QLQ-G.I.NET21 and EORTC QLQ-C30 domains not included among key secondary endpoints.

Absolute change from baseline in EORTC QLQ-G.I.NET21 domain

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

Quality of Life assessed by EORTC QLQ-G.I.NET21 (excluding GI scale) (domains not included as key secondary objectives)

Absolute change from baseline in the EQ-5D-5L index at each time point

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start

Quality of Life assessed by EQ-5D-5L

Absolute change from baseline in EORTC QLQ-C30 domain

Time frame · After observing approximately 88 PFS events as per BIRC assessment, expected after approximately 33 months from study start.

Quality of Life assessed by EORTC QLQ-C30 (domains not included as key secondary objectives)

Eligibility

Who can take part.

Minimum age
12 Years
Maximum age
100 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Presence of metastasized or locally advanced, unresectable (curative intent), histologically proven, well differentiated Grade 1 or Grade 2 (Ki-67 \<10%) gastroenteropancreatic neuroendocrine tumor (GEP-NET) diagnosed within 6 months prior to screening. * Participants with high disease burden in the Investigator's opinion. Following criteria should be used as the guiding principle for determining high disease burden: * Primary tumor or a metastatic lesion \> 4 cm * More than one tumor or metastatic lesions measuring \> 2 cm * Elevated alkaline phosphatase \> 2.5 X upper limit of normal (ULN) * Presence of bone metastasis * Presence of peritoneal metastasis * Symptoms due to tumor volume such as pain, fatigue, weight loss, anorexia etc. * Symptoms due to hormone excess requiring active management * Additionally, participants who, in the Investigator's opinion, have high disease burden due to their disease characteristics not specified above could also be considered eligible. * Participants ≥ 12 years of age. * RLI somatostatin receptor (SSTR) uptake on all target lesions (defined by RECIST v1.1 criteria) at least as high as normal liver uptake assessed within 3 months prior to randomization. Any of the RLI modalities as available (some examples are listed below) can be used as per local practice: * \[68Ga\]Ga-DOTA-TOC PET/CT or PET/MRI * \[68Ga\]Ga-DOTA-TATE PET/CT or PET/MRI * \[64Cu\]Cu-DOTA-TATE PET/CT or PET/MRI * Somatostatin receptor scintigraphy (SRS) (planar and/or SPECT/CT) with \[111In\]In-pentetreotide * SRS (planar and/or SPECT/CT) with \[99mTc\]Tc-octreotide. * Adequate bone marrow and organ function as defined by the following laboratory values prior to receiving the first study treatment: * White blood cell (WBC) count ≥ 2 x 109/L * Platelet count ≥ 75 x 109/L * Hemoglobin (Hb) ≥ 8 g/dL * Creatinine clearance \> 40 mL/min calculated by the Cockcroft Gault method * Total bilirubin ≤ 3 x ULN * Potassium within normal limits. Potassium level of up to 6.0 millimoles per liter (mmol/L) is acceptable at study entry if associated with creatinine clearance within normal limits calculated using Cockcroft-Gault formula. Mild decrease (grade 1) below lower limit of normal (LLN) is acceptable at study entry if considered not clinically significant by Investigator. * ECOG performance status 0-1. * Presence of at least 1 measurable site of disease. Exclusion Criteria: * Prior administration of a therapeutic radiopharmaceutical for GEP-NET at any time prior to randomization in the study. * Any previous therapy with interferons, mTOR-inhibitors, chemotherapy or other systemic therapies except somatostatin analogues (SSAs) of GEP-NET. If as per Investigator's opinion a participant is candidate for such therapies, such participant must not be enrolled. * Participant who received more than 4 cycles of prior SSAs (e.g., octreotide long-acting release) are not eligible. In addition, any participant receiving treatment with short-acting octreotide, which cannot be interrupted for 24 h before the administration of \[177Lu\]Lu-DOTA-TATE, or any participant receiving treatment with SSAs, which cannot be interrupted for at least 4 weeks before the administration of \[177Lu\]Lu-DOTA-TATE. * Documented RECIST v1.1 progression during previous SSA treatments for the current GEP-NET at any time prior to randomization. * Any previous radioembolization, chemoembolization and radiofrequency ablation for GEP-NET. * Any major surgery within 12 weeks prior to randomization in the study. * Known brain metastases. * Participant with known intolerance to CT scans with intravenous (i.v.) contrast due to allergic reaction or renal insufficiency. If such a participant can be imaged with MRI, then the participant would not be excluded. * Hypersensitivity to any somatostatin analogues, to the Investigational Medicinal Products (IMPs) active substance or to any of the excipients. * Active severe urinary incontinence, severe voiding dysfunction, or urinary obstruction requiring an indwelling/condom catheter that, in the judgment of the Investigator, could prevent adhering to radiation safety instructions. Other protocol-defined Inclusion/Exclusion criteria may apply.

Study locations

65 registered sites.

Canada · China · France · Germany · Hungary · Italy · Netherlands · Poland · South Korea · Spain · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.

Mayo Clinic Arizona

Scottsdale, Arizona, United States

Highlands Oncology Group

Fayetteville, Arkansas, United States

Rocky Mountain Cancer Centers

Denver, Colorado, United States

Hartford Hospital

Hartford, Connecticut, United States

Yale New Haven Hospital

New Haven, Connecticut, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Winship Cancer Institute

Atlanta, Georgia, United States

St Elizabeth Healthcare

Edgewood, Kentucky, United States

LSU Medical Center

New Orleans, Louisiana, United States

Henry Ford Hospital

Detroit, Michigan, United States

Mount Sinai Medical Center

New York, New York, United States

Piedmont Healthcare

Winston-Salem, North Carolina, United States

Tennessee Oncology

Nashville, Tennessee, United States

TxO Austin Midtown

Austin, Texas, United States

Texas Oncology

Dallas, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

Blue Ridge Cancer Center

Wytheville, Virginia, United States

Northwest Medical Specialties

Tacoma, Washington, United States

Novartis Investigative Site

Edmonton, Alberta, Canada

Novartis Investigative Site

London, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Beijing, China

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Pasireotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.